Safety and Efficacy of Zanubrutinib in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
Blood Adv 2023 Sep 08;[EPub Ahead of Print], SS Opat, A Tedeschi, B Hu, KM Linton, P McKay, S Leitch, M Coleman, PL Zinzani, J Jin, M Sun, M Sobieraj-Teague, PJ Browett, X Ke, C Thieblemont, KM Ardeshna, F Bijou, PA Walker, EA Hawkes, SJ Ho, K Zhou, Z Liang, J Xu, C Tankersley, R Delarue, M Co, J TrotmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.